Brent A. Batzer

Brent A. Batzer is an intellectual property attorney whose practice centers on patent litigation, with a particular focus on the pharmaceutical industry. His work frequently involves Hatch-Waxman (Paragraph IV) litigation, where he has represented both brand-name and generic drug companies. This dual perspective is informed by his background in chemical engineering. In addition to his pharmaceutical specialty, Batzer has litigated patent cases in the fields of medical devices, dietary supplements, mechanical inventions, and gaming technology.

Based on the single tracked case, Portus Singapore Pte Ltd. v. AXP Group (Vivint), Batzer appeared for the defendant. His broader practice description indicates that he works on both the plaintiff (brand) and defense (generic) sides in the pharmaceutical sector. Public records from 2024 show him representing generic applicant Zenara Pharma Pvt. Limited in district court litigation and co-authoring an amicus brief on behalf of Deva Holding A.S. before the Federal Circuit.

Batzer is currently a team leader at Upadhye Tang LLP (also operating as IP & FDA Lawyers). The authoritative case data lists his appearance in the Portus Singapore matter with the firm Vinson & Elkins, though his current firm biography does not detail prior affiliations. He has experience with appeals to the U.S. Court of Appeals for the Federal Circuit and has authored articles on post-grant proceedings, such as Inter Partes Review (IPR), indicating experience with PTAB matters.

He earned a J.D., cum laude, from the University of Michigan Law School and a B.S. in Chemical Engineering, magna cum laude, from Case Western Reserve University. Batzer is admitted to the Illinois bar and the U.S. Court of Appeals for the Federal Circuit.